Literature DB >> 16820223

Transport of glutathione and glutathione conjugates by MRP1.

Susan P C Cole1, Roger G Deeley.   

Abstract

Glutathione (GSH)-conjugated xenobiotics and GSH-conjugated metabolites (e.g. the cysteinyl leukotriene C4) must be exported from the cells in which they are formed before they can be eliminated from the body or act on their cellular targets. This efflux is often mediated by the multidrug resistance protein 1 (MRP1) transporter, which also confers drug resistance to tumour cells and can protect normal cells from toxic insults. In addition to drugs and GSH conjugates, MRP1 exports GSH and GSH disulfide, and might thus have a role in cellular responses to oxidative stress. The transport of several drugs and conjugated organic anions by MRP1 requires the presence of GSH, but it is not well understood how GSH (and its analogues) enhances transport. Site-directed mutagenesis studies and biophysical analyses have provided important insights into the structural determinants of MRP1 that influence GSH and GSH conjugate binding and transport.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16820223     DOI: 10.1016/j.tips.2006.06.008

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  104 in total

Review 1.  Collateral sensitivity as a strategy against cancer multidrug resistance.

Authors:  Kristen M Pluchino; Matthew D Hall; Andrew S Goldsborough; Richard Callaghan; Michael M Gottesman
Journal:  Drug Resist Updat       Date:  2012-04-06       Impact factor: 18.500

2.  The "specific" P-glycoprotein inhibitor Tariquidar is also a substrate and an inhibitor for breast cancer resistance protein (BCRP/ABCG2).

Authors:  Pavitra Kannan; Sanjay Telu; Suneet Shukla; Suresh V Ambudkar; Victor W Pike; Christer Halldin; Michael M Gottesman; Robert B Innis; Matthew D Hall
Journal:  ACS Chem Neurosci       Date:  2010-10-21       Impact factor: 4.418

3.  Promoter polymorphism of MRP1 associated with reduced survival in hepatocellular carcinoma.

Authors:  Jing Zhao; Bing-Yun Yu; Dao-Yuan Wang; Jin-E Yang
Journal:  World J Gastroenterol       Date:  2010-12-28       Impact factor: 5.742

4.  Effect of alcohol on drug efflux protein and drug metabolic enzymes in U937 macrophages.

Authors:  Mengyao Jin; Priyanka Arya; Kalpeshkumar Patel; Bhupendra Singh; Peter S Silverstein; Hari K Bhat; Anil Kumar; Santosh Kumar
Journal:  Alcohol Clin Exp Res       Date:  2010-10-06       Impact factor: 3.455

Review 5.  The Nrf2-ARE cytoprotective pathway in astrocytes.

Authors:  Marcelo R Vargas; Jeffrey A Johnson
Journal:  Expert Rev Mol Med       Date:  2009-06-03       Impact factor: 5.600

6.  A promiscuous conformational switch in the secondary multidrug transporter MdfA.

Authors:  Nir Fluman; Devora Cohen-Karni; Tali Weiss; Eitan Bibi
Journal:  J Biol Chem       Date:  2009-10-05       Impact factor: 5.157

7.  Chrysin enhances doxorubicin-induced cytotoxicity in human lung epithelial cancer cell lines: the role of glutathione.

Authors:  Heather M Brechbuhl; Remy Kachadourian; Elysia Min; Daniel Chan; Brian J Day
Journal:  Toxicol Appl Pharmacol       Date:  2011-08-10       Impact factor: 4.219

8.  Avermectin transepithelial transport in MDR1- and MRP-transfected canine kidney monolayers.

Authors:  David J Brayden; Joanna Griffin
Journal:  Vet Res Commun       Date:  2007-06-20       Impact factor: 2.459

9.  Negative regulation of the yeast ABC transporter Ycf1p by phosphorylation within its N-terminal extension.

Authors:  Christian M Paumi; Matthew Chuk; Igor Chevelev; Igor Stagljar; Susan Michaelis
Journal:  J Biol Chem       Date:  2008-07-29       Impact factor: 5.157

Review 10.  Pseudoxanthoma elasticum: clinical phenotypes, molecular genetics and putative pathomechanisms.

Authors:  Qiaoli Li; Qiujie Jiang; Ellen Pfendner; András Váradi; Jouni Uitto
Journal:  Exp Dermatol       Date:  2008-10-22       Impact factor: 3.960

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.